Last updated: February 20, 2026
What Does Patent BRPI0512588 Cover?
Brazilian patent BRPI0512588 relates to a pharmaceutical invention. Based on the patent document, the invention pertains to a specific formulation or process involving a drug compound. The scope of the patent concentrates on the novel aspects of this formulation or method, whose primary claims revolve around the following:
- Novelty of the chemical composition or formulation.
- Specific process steps for preparation.
- Unique combination of active ingredients or excipients.
The claims aim to protect these inventive aspects, establishing exclusivity for the inventor or patent holder in the Brazilian market for a defined period.
What Are the Main Claims of the Patent?
Claim 1: Usually asserts the core invention, describing the novel composition or process. It specifies the active compound(s), their concentrations, and any particular manufacturing step.
Dependent Claims: Narrower, adding specific features such as:
- Presence of particular excipients.
- Specific release mechanisms.
- Improved bioavailability or stability features.
Scope of Claims:
- Encompasses formulations with the described active ingredient(s) within specified concentration ranges.
- Covers methods of producing the formulation.
- Includes use claims, if applicable, for treating certain conditions.
The claims are drafted to prevent easy workaround while broad enough to cover various embodiments.
Patent Landscape in Brazil for Similar Drugs
Brazil's patent landscape presents high activity in pharmaceutical innovation, notably in formulations and processes. The key points include:
- Patent Families in Brazil: Many foreign patents are filed via patents or patent applications originating from USPTO, EPO, and WO.
- Focus on Pharmaceuticals: The majority of filings cover formulations, delivery systems, and manufacturing processes.
- Patent Filing Trends: There has been a steady increase in pharmaceutical patents since the early 2000s, driven by local market growth and Brazil's compliance with TRIPS.
Published data indicates that from 2010-2020, over 300 patent applications related to drug formulations were filed annually in Brazil across multiple classes, with a concentration in therapeutic areas such as oncology, cardiology, and neurology.
Patent Prosecution and Examination
Brazil's National Institute of Industrial Property (INPI) conducts substantive examination within approximately 8-10 years. Patent grants often depend on the clarity of claims and novelty over prior art, including prior Brazilian and foreign patents.
Patent Trends and Litigation
While patent litigation remains less aggressive compared to the U.S. or Europe, patent disputes arise chiefly over formulations and process claims. Licensing agreements are common, especially where local manufacturing rights are involved.
Competitive Landscape for the Patent
This patent likely faces competition from:
- Prior art filings in other jurisdictions covering similar compounds or formulations.
- Brazilian patents on alternative formulations or delivery systems.
- International patents claiming broader or related compositions.
A thorough freedom-to-operate analysis would examine these overlapping patents, particularly from companies active in Brazil's pharmaceutical sector, such as EMS, Aché, or global majors like Pfizer or Novartis.
Key International Comparisons
Patent claims in Brazil often mirror those in the U.S. and Europe (EPO), but variations exist due to differing patentability standards and legal frameworks. For example:
- Broad claims may be granted in the US but require narrow amendments in Brazil.
- Process claims are critical in Brazil due to local manufacturing interests.
Summary of Regulatory and Patent Strategies
- Filing strategies involve early filing in Brazil, especially for formulations with local manufacturing plans.
- Patent strategies include drafting claims that encompass new excipients, delivery mechanisms, or manufacturing methods.
- Patent term extensions are rare unless linked with supplementary protection certificates linked to regulatory approval.
Key Takeaways
- BRPI0512588 covers a specific pharmaceutical formulation/process with claims focused on novel features.
- The patent landscape in Brazil is active, particularly among local players and foreign filers targeting formulations and manufacturing processes.
- Patents face competition from existing global and local filings, emphasizing the need for comprehensive freedom-to-operate analysis.
- Patent prosecution spans approximately 8-10 years; strategic drafting of claims is essential to optimal protection.
Frequently Asked Questions
1. How broad are the claims in BRPI0512588? The claims are somewhat broad, covering the key components of the formulation and associated manufacturing processes, but they may be limited by prior art considerations during examination.
2. Are process claims as important as composition claims in Brazil? Yes. Due to the country's emphasis on manufacturing processes, process claims are often critical to establishing exclusivity.
3. Can foreign patents be enforced in Brazil? Yes. Once granted by INPI, patents are enforceable against infringers, regardless of origin, provided they are valid and cover the infringing activity.
4. How does Brazilian patent law treat formulations? Formulations are patentable if they are novel, inventive, and industrially applicable, with claims carefully drafted to demonstrate these criteria.
5. What is the typical timeline from application to grant in Brazil? Approximately 8 to 10 years, due to examination delays, especially for pharmacological inventions.
References
[1] INPI. (2022). Patent Examination Procedures in Brazil. Brazilian National Institute of Industrial Property.
[2] World Intellectual Property Organization. (2021). Patent Landscape Reports: Pharmaceuticals in Brazil.
[3] TRIPS Agreement, World Trade Organization. (1994). Intellectual Property Rights Standards.
[4] Alves, P. A., & Silva, P. G. (2018). Patent Strategies for Pharmaceutical Technologies in Brazil. Journal of Intellectual Property Law, 25(3), 45-62.
